Inactive Instrument

Alseres Pharmaceuticals, Inc. Stock Other OTC

ALSE

US0211522026

Latest news : Alseres Pharmaceuticals, Inc.

21/04/15	Alseres Pharmaceuticals, Inc. cancelled the acquisition of E-IACFT Injection from Navidea Biopharmaceuticals, Inc.	CI
29/01/15	Alseres Pharmaceuticals, Inc. will Change its Ticker to ALSE from ALSED	CI
10/04/14	Alseres Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
01/04/13	Alseres Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
06/08/12	Alseres Pharmaceuticals, Inc. Licenses Altropane Rights to Navidea Biopharmaceuticals	CI
06/08/12	Alseres Pharmaceuticals, Inc. entered into an agreement to acquire E-IACFT Injection from Navidea Biopharmaceuticals, Inc for $3.4 million.	CI
03/08/12	Alseres Pharmaceuticals, Inc. Taken Out Licensing Agreement with Alseres Pharmaceuticals, Inc	CI
31/07/12	Alseres Pharmaceuticals, Inc. Reports License of Altropane(R) Worldwide Rights to Navidea Biopharmaceuticals, Inc	CI
17/07/12	Alseres Pharmaceuticals, Inc. announced that it has received $34.4 million in funding from Highbridge Capital Management, LLC, Ingalls & Snyder LLC, and other investors.	CI
02/07/12	Navidea Biopharmaceuticals to Continue its Diligence Through the End of July 2012 with Alseres Pharmaceuticals, Inc. to License E-IAFCT Injection	CI
29/03/12	Alseres Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
27/01/12	Navidea Biopharmaceuticals, Inc. Signs Option Agreement with Alseres Pharmaceuticals, Inc., to License Altropane	CI

More news

Diagnostic & Testing Substances Manufacturers

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALSERES PHARMACEUTICALS, INC.	-.--%	-.--%	-	-	30
ULTRAGENYX PHARMACEUTICAL INC.	+8.83%	+16.10%	-8.17%	-27.62%	3.01B
SAREPTA THERAPEUTICS, INC.	+5.58%	+4.11%	+5.09%	-84.31%	1.8B
BIONOTE, INC.	+1.00%	-0.76%	-9.98%	+0.33%	296M
DK LIFE SCIENCE CO., LTD.	-2.37%	-7.66%	-44.62%	-	52.45M
Average	+2.61%	+1.22%	-14.42%	-37.20%	1.29B
Weighted average by Cap.	+7.13%	+2.21%	-4.02%	-45.95%

See all sector performances

Alseres Pharmaceuticals, Inc. is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). The Company's lead product candidate is Altropane. The Company's Altropane product is a molecular imaging agent used to diagnose Parkinson's disease and dementia. The Company is focused on entering into partnerships to ensure development and commercialization of its product.

Employees

Sector

Pharmaceuticals

More about the company